Prelude Therapeutics Welcomes Katina Dorton, J.D., MBA, To Its Board of Directors

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced the appointment of Katina Dorton to its Board of Directors, effective immediately. Ms. Dorton brings more than 30 years of experience in healthcare and life sciences, including leadership roles in executive finance, investment banking, and service on the boards of public life science companies. Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, stated that Ms. Dorton’s extensive strategic and financial expertise will be valuable to the leadership team. He expressed enthusiasm for her immediate contributions as the company continues to advance its precision oncology drug candidates.

Ms. Dorton most recently served as Chief Financial Officer at NodThera. Prior to that, she built and led the finance organization for Repare Therapeutics, preparing the company for its IPO and raising over $82 million in crossover funding. She has also held senior finance roles at AVROBIO, Inc. and Immatics N.V. Before joining the biopharmaceutical industry, Ms. Dorton spent 15 years in investment banking at Morgan Stanley and Neeham & Co. She currently serves on the boards of Mallinckrodt Pharmaceuticals plc, Fulcrum Therapeutics, TScan Therapeutics, and Sonoma Biotherapeutics. 

Ms. Dorton holds a B.A. from Duke University, an M.B.A. from George Washington University, and a J.D. from the University of Virginia School of Law. Ms. Dorton commented on her appointment, highlighting Prelude’s strong leadership team, exciting pipeline of novel precision oncology drug candidates, and the potential to create significant shareholder value. She expressed enthusiasm about working closely with the leadership team and fellow board members to guide the company toward achieving its strategic objectives.

Ms. Dorton will succeed Mardi C. Dier, who will resign from the Prelude board effective October 17, 2025. She will also assume Ms. Dier’s role as Audit Committee Chair. Ms. Dier has served on the board since August 2020. Dr. Vaddi thanked Ms. Dier for her dedicated service and significant contributions to Prelude since the company became public in 2020, noting her importance as a professional resource to the executive leadership team and wishing her continued success in future endeavors.